- 86 Downloads
▴ Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel ζ2-δ proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmitter release caused by binding to the α2-δ protein, resulting in allosteric modulation of P/ Q-type voltage-gated calcium channels.
▴ In three well designed trials, oral pregabalin as adjunctive therapy in patients with refractory partial seizures was significantly (p ≤ 0.0007) more effective than placebo in reducing seizure frequency when administered at dosages of 150–600 mg/day (as two or three divided doses).
▴ Adjunctive pregabalin produced an overall mean 41.3% improvement from baseline in 28-day seizure-free rate in four long-term (maximum exposure 1764 days), open-1abel studies in 1480 patients.
▴ CNS-related effects (e.g. dizziness and somnolence) were the most frequent dose-related treatment-emergent adverse events associated with adjunctive pregabalin therapy.
KeywordsPregabalin Alprazolam Partial Seizure Seizure Frequency Diabetic Peripheral Neuropathy
- 5.Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drags. In pressGoogle Scholar
- 8.McClelland D, Evans RM, Barkworth L, et al. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats. BMC Pharmacol 2004 Aug 4; 4 (14) [online]. Available from URL: http://www.biomedcentral.com/1471-2210/4/14 [Accessed 2005 Feb 3]
- 15.Taylor CP, Vartanian MG. Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models [abstract no. 1.109]. Epilepsia 1997; 38Suppl. 8: 35Google Scholar
- 16.Hindmarch I, Dawson J, Stanley N. Evaluation of cognitive and psychomotor profile of pregabalin compared to alprazolam in normal volunteers [abstract no. NR206 plus poster]. American Psychiatric Association 2002 Annual Meeting: New Research Abstracts; 2002 May 18–23; Philadelphia, 56Google Scholar
- 17.Hindmarch I, Dawson J, Stanley N. Evaluation of the sleep activity profile of pregabalin compared to alprazolam in normal volunteers [abstract no. NR415 plus poster]. American Psychiatric Association 2002 Annual Meeting: New Research Abstracts; 2002 May 18–23; Philadelphia, 112Google Scholar
- 18.Morrell M, Brigell M, Chartier K, et al. A double-blind, placebo-controlled, parallel-group study to assess the effects of pregabalin on reproductive function in healthy males [abstract no. P04.096]. Neurology 2004; 62Suppl. 5: A314Google Scholar
- 19.Busch JA, Strand JC, Posvar EL, et al. Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses [abstract no. 2.108]. Epilepsia 1998; 39Suppl. 6: 58Google Scholar
- 21.Bockbrader HN, Wesche D. Pharmacokinetic profile of pregabalin: results of a series of studies [abstract no. NR378]. American Psychiatric Association 2004 Annual Meeting: New Research Abstracts; 2004 May 1–6; New York, 140-1Google Scholar
- 22.Corrigan BW, Pool WF, Posvar EL, et al. Metabolic disposition of pregabalin in healthy volunteers [abstract no. PI-68]. Clin Pharmacol Ther 2001 Feb; 69(2): 18Google Scholar
- 23.Bockbrader HN, Hunt T, Strand J, et al. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase 1 studies [abstract no. P06.051]. Neurology 2000 Apr 11; 54Suppl. 3: A421Google Scholar
- 24.Corrigan B, Bockbrader H, Burger P, et al. Pregabalin population pharmacokinetics in patients with refractory partial seizures [abstract no. P452]. Epilepsia 2002; 43Suppl. 8: 144–5Google Scholar
- 26.Bockbrader H, Burger P, Kugler A, et al. The oral clearance (CL/F) of commonly prescribed antiepileptic drugs (AEDs) is unaffected by concomitant administration of pregabalin in adult patients with refractory partial seizures [abstract no. P453]. Epilepsia 2002; 43Suppl. 8: 145Google Scholar
- 27.Bockbrader HN, Posvar EL, Hunt T, et al. Pregabalin does not alter the effectiveness of an oral contraceptive [abstract no. P04.097]. Neurology 2004; 62Suppl. 5: A314Google Scholar
- 32.Guberman A, Anhut H, Lee C, et al. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible and fixed dosing [abstract no. P04.095]. Neurology 2004; 62Suppl. 5: 313–4Google Scholar
- 33.Spiegel K, Baulac M, Lee CM, et al. Long-term seizure freedom in patients with partial seizures treated with add-on pregabalin: an analysis of four, long-term, open-1abel trials [abstract no. P04.098]. Neurology 2004; 62Suppl. 5: 314–5Google Scholar
- 34.Greiner MJ, Lee CM, Knapp LE, et al. Pregabalin shows efficacy in reducing simple partial, complex partial, and secondarily generalized seizures [abstract no. P04.099]. Neurology 2004; 62Suppl. 5: 315Google Scholar
- 36.Asconape JJ, Hartman LM, Salanova V, et al. Pregabalin-associated myoclonus [abstract no. 2.238]. Epilepsia 1999; 40Suppl. 7: 143Google Scholar
- 37.Pfizer. Lyrica® summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=14651 [Accessed 2005 Jan 10]
- 38.New seizure medicine may be approved soon [online]. Available from URL: http://www.epilepsy.com/web/print.php?page_name=ar_l068495353 [Accessed 2004 Jun 23]
- 39.Pfizer Inc. Pfizer statement on regulatory status of Lyrica [online]. Available from URL: http://www.pfizer.com/are/news_releases/2004pr/mn_2004_0902.html [Accessed 2004 Sep 9]
- 40.Pfizer Inc. FDA approves Pfizer’s Lyrica™ for the treatment of the two most common forms of neuropathic (nerve) pain [online]. Available from URL: http://www.pfizer.com/are/investors_releases/2004pr/mn_2004_1231.cfm [Accessed 2004 Dec 31]